https://www.medrxiv.org/content/10.1101/2021.08.27.21262356v1 These persons are excluded from the proportions of race/ethnicity but are included in other analyses. https://www.cdc.gov/mmwr/volumes/70/wr/mm7050e2.htm, Adults who completed their primary COVID-19 vaccination series were defined as those who had received the second dose of a 2-dose primary vaccination series or a single dose of a 1-dose primary vaccine product 14 days before receipt of a positive SARS-CoV-2 test result associated with their hospitalization but received no additional or booster dose. The second study, led by Office for National Statistics researchers in Wales, involved death rates and risk factors in adults in England who had received an mRNA booster at least 14 days before Dec 31, 2021. Infect. Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life. These trends could result in epidemic phase bias if infection severity is correlated with time from infection to test. On March 18, 2022, this report was posted online as an MMWR Early Release. We monitored the seroprevalence of SARS-CoV-2 nucleocapsid (anti-N) and spike protein (anti-S) antibodies in blood donors across Canada from September 2021 to June 2022 in 202,123 . Other studies found similarly decreased proportions of severe outcomes among hospitalized patients with COVID-19 during this period (6).. 139, e20164091 (2017). Zerbo, O., Ray, G.T., Fireman, B. et al. Data from the COVID-19Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to compare COVID-19associated hospitalization rates among adults aged 18 years during B.1.617.2 (Delta; July 1December 18, 2021) and Omicron (December 19, 2021January 31, 2022) variant predominance, overall and by race/ethnicity and vaccination status. Andrews, N. et al. Morb. Wkly. These cookies may also be used for advertising purposes by these third parties. Most mothers (66.14%) were between ages 25 and <35 years, and more than a quarter (27.27%) were of Asian race, 5.16% were Black, 24.44% were of Hispanic ethnicity and 37.57% were White. This case-positive, control-test-negative design also referred to as the test-negative design (TND) has often been used in studies of vaccine effectiveness. We did not assess whether vaccines received before pregnancy or immediately after pregnancy were associated with a reduced risk of testing positive for SARS-CoV-2 in infants. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. PLoS ONE 15, e0229279 (2020). Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. Cookies used to make website functionality more relevant to you. Surveillance officers abstracted data on sampled patients from medical charts. Vaccine effectiveness for 1 dose during the first 6 months of life was 68% (95% CI: 12, 88) (Table2). All authors (O.Z., B.F., N.P.K., T.R., M.G., E.L., P.R., K.G., S.O., and E.L.) critically reviewed the manuscript and decided to proceed with publication. This is a relevant consideration because vaccines can be less effective in persons with a weakened immune system. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. You are using a browser version with limited support for CSS. All other authors declare no competing interests. Hospitalizations rates increased among all adults irrespective of vaccination status (unvaccinated, primary series only, or primary series plus a booster or additional dose). N. Engl. All rights Reserved. J. Obstet. Vaccine 31, 31043109 (2013). Office of the Vice President for Research, University of Minnesota, Minneapolis, MN, 2023 Regents of the University of Minnesota.
Defined as one or more of the following: chronic lung disease including asthma, chronic metabolic disease including diabetes mellitus, blood disorder/hemoglobinopathy, cardiovascular disease, neurologic disorder, immunocompromising condition, renal disease, gastrointestinal/liver disease, rheumatologic/autoimmune/inflammatory condition, obesity, feeding tube dependency, and wheelchair dependency. Adults who received booster doses were classified as those who completed their primary vaccination series and received an additional or booster dose of vaccine on or after August 13, 2021, at any time after the completion of their primary series, and 14 days before a positive test result for SARS-CoV-2, because COVID-19associated hospitalizations are a lagging indicator, and time passed after receipt of a booster dose has been shown to be associated with reduced rates of COVID-19 infection (https://www.nejm.org/doi/full/10.1056/NEJMoa2114255). https://www.cdc.gov/nchs/nvss/bridged_race.htm, ** https://www.medrxiv.org/content/10.1101/2021.08.27.21262356v1, On August 13, 2021, CDCs Advisory Committee on Immunization Practices (ACIP) issued the first of several recommendations for additional or booster doses of COVID-19 vaccine.
(2021) Omicron is supercharging the COVID vaccine booster debate. 4% of cases) without NHS numbers were excluded from our primary analysis.
JAMA Netw Open 2021;4:e2130479. The study was funded by the National Institute of Allergy and Infectious Disease grant # 1R01AI168373-01 to O.Z. part 56; 42 U.S.C. Female sex was a protective factor (HR, 0.52), while residence in a nursing home or low-income area was a risk factor. Vaccinated patients were older (68 vs. 57 years), and 62% had at least one comorbidity Admission to the ICU was 20%, and the mortality rate at 30 days was 14%. The research was published yesterday in JAMA Internal Medicine. Selected counties in California, Colorado, Connecticut, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah (https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm). In the US, as of the end of September 2022, almost 15 million children ages <18 years have tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus Disease 2019 (COVID-19). 40, e137e145 (2021). There were only one hospitalized case among the children of vaccinated mothers and nine hospitalized cases among the children of unvaccinated mothers (Table1). Mortal. Partially vaccinated adults, and those who received a single dose of a 1-dose product <14 days before the positive SARS-CoV-2 test result were not included in analyses by vaccination status but were included in rates and overall proportions that were not stratified by vaccination status. Finally, we conducted additional supplemental analyses to estimate VE among children whose mothers received at least one vaccine dose prior to pregnancy onset and at least one dose during pregnancy. Because the immune status of all patients is not known, an additional dose (recommended for persons with a weakened immune system) cannot be distinguished from a booster dose. These findings are consistent with the diminishing of pregnancy-derived antibodies in infants over time22. To update your cookie settings, please visit the, https://doi.org/10.1016/S0140-6736(22)00462-7, Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study, https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern, https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html, https://www.mrc-bsu.cam.ac.uk/now-casting/report-on-nowcasting-and-forecasting-9th-december-2021/, https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022.pdf, https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness-, https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-50-severity-omicron/, https://doi.org/10.1101/2022.01.11.22269045, https://doi.org/10.1101/2022.01.12.22269179, https://doi.org/10.1101/2022.01.20.22269406, https://doi.org/10.1101/2022.01.12.22269148, https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6.pdf, https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-routine-variant-data-update, https://www.gov.uk/government/publications/nhs-test-and-trace-statistics-england-methodology/nhs-test-and-trace-statistics-england-methodology, https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/, https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-sets/emergency-care-data-set-ecds, https://digital.nhs.uk/services/secondary-uses-service-sus, https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/, https://doi.org/10.1101/2021.08.13.21262014, View Large O.Z. All authors reviewed the manuscript. The study provides evidence that a previous omicron infection in triple-vaccinated individuals provides high amounts of protection against BA.5 and BA.2 infections. What are the implications for public health practice? Maternal vaccination and risk of hospitalization for Covid-19 among infants. Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birtheight integrated Health Care Organizations, United States, December 15, 2020-July 22, 2021. Rep. 71, 2630 (2022). These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. TN and NMF were responsible for visualisation. The final study population included 30311 (48.8%) infants who were KPNC members at least 2 months after birth.
Biomedicines | Free Full-Text | Risk Stratification Model for Severe Sect. China informed the WHO about the case, which involves a 53-year-old woman, on Feb 24. Pediatr. Google Scholar. During the Omicron-predominant period, peak hospitalization rates among non-Hispanic Black (Black) adults were nearly four times the rate of non-Hispanic White (White) adults and was the highest rate observed among any racial and ethnic group during the pandemic. These proportions are lower compared with 47.3% of White persons who received a primary series and 54.5% of eligible adults who received a booster dose. Relative to the Delta-predominant period, Black adults accounted for a larger proportion of unvaccinated adults during the Omicron-predominant period, and age-adjusted hospitalization rates for Black adults increased to the highest rate among all racial and ethnic groups for any week during the pandemic. Author's reply, Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India, Centers for Disease Control and Prevention, MRC Biostatistics Unit COVID-19 Working Group, Cases, hospital admissions, and hospital attendances in those with delta and omicron SARS-CoV-2 variants, between Nov 29, 2021, and Jan 9, 2022, Risk of hospitalisation and mortality for COVID-19 cases with omicron compared with delta, overall and by age group, Estimated HRs for vaccination categories, secondary analysis. Sadoff, J. et al. Protection during both periods decreased as infants aged. The results were published yesterday in JAMA Network Open. JAMA Netw. During the study period, the omicron variant experienced a rapidly increasing incidence, whereas the delta variant was experiencing a decreasing or less rapidly increasing incidence. Lipkind, H. S. et al. American Academy of Pediatrics. Receipt of one dose especially during the third trimester was also associated with a reduced risk of infants testing positive for SARS-CoV-2 during the first 6 months of life during the Delta dominant period. This preceded and had no relation to COVID-19, and GD had no role in and received no funding from the project. N. Engl. Includes current treatment or recent diagnosis of an immunosuppressive condition or use of an immunosuppressive therapy during the preceding 12 months. Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life, https://doi.org/10.1038/s41467-023-36547-4. Access your favorite topics in a personalized feed while you're on the go. SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland, Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy, Effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy: a national observational study in Israel, Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study, Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain, Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults, The indirect effect of mRNA-based COVID-19 vaccination on healthcare workers unvaccinated household members, SARS-CoV-2 infection and COVID-19 vaccination in pregnancy, Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar, https://downloads.aap.org/AAP/PDF/AAP%20and%20CHA%20-%20Children%20and%20COVID-19%20State%20Data%20Report%209.29.22%20FINAL.pdf?_ga=2.255000394.335550773.1665001859-370326403.1636740765, https://doi.org/10.1016/j.jpeds.2022.09.059, http://creativecommons.org/licenses/by/4.0/. The rate among adults who received a primary series, but no booster or additional dose, was three times the rate among adults who received a booster or additional dose. Corresponding author: Christopher A. Taylor, iyq3@cdc.gov. Christopher A. Taylor, PhD1; Michael Whitaker, MPH1; Onika Anglin, MPH1,2; Jennifer Milucky, MSPH1; Kadam Patel, MPH1,2; Huong Pham, MPH1; Shua J. Chai, MD3,4; Nisha B. Alden, MPH5; Kimberly Yousey-Hindes, MPH6; Evan J. Anderson, MD7,8,9; Kenzie Teno, MPH10; Libby Reeg, MPH11; Kathryn Como-Sabetti, MPH12; Molly Bleecker, MA13; Grant Barney, MPH14; Nancy M. Bennett, MD15; Laurie M. Billing, MPH16; Melissa Sutton, MD17; H. Keipp Talbot, MD18; Keegan McCaffrey19; Fiona P. Havers, MD1; COVID-NET Surveillance Team (View author affiliations). ***** An additional 172 (3.4%, 95% CI=2.7%4.2%) adults were partially vaccinated, 69 (0.9%, 95% CI=0.61.2) received a primary vaccination series <14 days before a positive for SARS-CoV-2 test result, and 186 (4.1%) had unknown vaccination status; these groups are not further described in this analysis. Published by Elsevier Ltd. The data cannot be shared publicly because the data contain potentially identifying or sensitive patient information and is legally restricted by Kaiser Permanente Northern California. All adults should stay up to date (1) with COVID-19 vaccination to reduce their risk for COVID-19associated hospitalization. In this analysis, we estimated the odds ratio (OR) of vaccination of mothers of infants who tested positive for SARS-CoV-2 versus infants who tested negative using logistic regression models conditioned (stratified) on the calendar date of the test so that infants testing positive on a certain day were compared to infants testing negative on that same day. Among children 12 to 17, the . Introduction: A rapid increase in COVID-19 cases due to the spread of the Delta and Omicron variants in vaccinated populations has raised concerns about the hospitalization risk associated with, and the effectiveness of, COVID-19 vaccines. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant.